PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy [0.03%]
前列腺癌诊断和治疗的PSMA靶向放射性药物
Jorge D Oldan,Frankis Almaguel,Andrew F Voter et al.
Jorge D Oldan et al.
Prostate cancer (PCa) is the most common noncutaneous malignancy in men. Until recent years, accurate imaging of men with newly diagnosed PCa, or recurrent or low-volume metastatic disease, was limited. Further, therapeutic options for men ...
Positron Emission Tomography Imaging of Tumor Proliferation and DNA Repair [0.03%]
肿瘤增殖和DNA修复的正电子发射断层扫描影像学研究
Anthony F Shields,Delphine L Chen
Anthony F Shields
Positron emission tomography (PET) is an established tool for molecular imaging of cancers, and its role in diagnosis, staging, and phenotyping continues to evolve and expand rapidly. PET imaging of increased glucose utilization with 18F-fl...
Austin R Pantel,Seong-Woo Bae,Elizabeth J Li et al.
Austin R Pantel et al.
Imaging glucose metabolism with [18F]fluorodeoxyglucose positron emission tomography has transformed the diagnostic and treatment algorithms of numerous malignancies in clinical practice. The cancer phenotype, though, extends beyond dysregu...
Benjamin M Larimer
Benjamin M Larimer
Cancer immunotherapy, including checkpoint blockade and cellular therapy, has become a cornerstone in cancer treatment. However, understanding the factors driving patient response or resistance to these therapies remains challenging. The dy...
Quinton J Keigley,Amy M Fowler,Sophia R O&#x;Brien et al.
Quinton J Keigley et al.
Steroid receptors regulate gene expression for many important physiologic functions and pathologic processes. Receptors for estrogen, progesterone, and androgen have been extensively studied in breast cancer, and their expression provides p...
Nuclear Medicine Cancer Care-Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer [0.03%]
核医学肿瘤诊疗现状及未来展望：放射性药物诊断与治疗分子影像的作用
Sophia R O&#x;Brien,David A Mankoff
Sophia R O&#x;Brien
Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma [0.03%]
细胞周期检查点p16和p21是高分级骨肉瘤临床病理结果的强预测因子
Elham Nasri,Dianne E Torrence,Terrie Vasilopoulos et al.
Elham Nasri et al.
Purpose: In this study, we used a series of immunohistochemical measurements of 2 cell cycle regulators, p16 and p21, to evaluate their prognostic value, separately and in combination, for the disease outcomes. ...
Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care [0.03%]
标准治疗后进展的黑色素瘤患者的治疗研究方法
Kylie A Fletcher,Douglas B Johnson
Kylie A Fletcher
The advent of effective immunotherapy, specifically cytotoxic T-lymphocyte associated protein 4 and programmed cell death 1 inhibitors, as well as targeted therapy including BRAF/MEK inhibitors, has dramatically changed the prognosis for me...
Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma? [0.03%]
黑色素瘤的综合化疗或大剂量干扰素Ⅱ目前还有作用吗？
Julie Fishman,Elizabeth I Buchbinder
Julie Fishman
Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable ...
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma [0.03%]
用于转移性黑色素瘤的肿瘤浸润淋巴细胞及其他细胞疗法
Christy Los,Sebastian Klobuch,John B A G Haanen
Christy Los
Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing...